OCTOBER 2014 Caldolor ®  improves recovery in  adult surgery patients MAY 2014 Cumberland reports return to  profitability MARCH 2014 Caldolor ®  reduces fever in pediatric patients  MAY 2014  Cumberland launches Vaprisol ® promotion MAY 2014 JANUARY 2014  MARCH 2014 Cumberland announces acquisition  of Vaprisol ®  from Astellas Pharma  Cumberland and Gloria  Pharmaceuticals announce  joint research and development  investment Cumberland’s field sales force  begins promoting Omeclamox-Pak  to gastroenterologists across the  nation. Cumberland begins promotion and  distribution of Omeclamox ® -Pak China’s Gloria Pharmaceuticals  and Cumberland together invest $2  million in Cumberland Emerging  Technologies to accelerate the  development of new product  candidates from regional research  centers. CET is majority owned by  Cumberland in partnership with  Vanderbilt University, the state of  Tennessee and Gloria – our new  international partner.  Cumberland acquires all assets  and assumes full responsibility to  market, distribute and manufacture  Vaprisol.  Data from a pediatric study  demonstrates the safety and  efficacy of Caldolor in reducing fever  in hospitalized children. Caldolor  is associated with statistically  significant reduction in temperature  within the first two hours of dosing. Cumberland launches active sales  and marketing campaign to support  Vaprisol. Results from an investigator study  show preoperative intravenous  ibuprofen improved the overall  quality of recovery including  comfort, emotion and pain in  patients undergoing laparoscopic  cholecystectomy (gallbladder  removal) surgery. In its first quarter earnings release,  Cumberland reports its return  to profitability through growth in  sales of established brands and the  addition of new product sales.  international partner.  2014 Milestones 2